Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Endogenous retrovirus group K3 member 1 (ERVK3-1)
- Target
- ERVK3-1
- Molecular classification
- Retroviral element, Endogenous retrovirus (HERV), LncRNA (for specific readthrough variants), Other
01
Overview
Endogenous retrovirus group K3 member 1 (ERVK3-1) is a human endogenous retroviral sequence belonging to the HERV-K (HML-6) family, present on chromosome 19. These elements are remnants of ancient retrovirus infections and constitute approximately 8% of the human genome. ERVK3-1 retains an intact open reading frame and is expressed as transcripts in various healthy tissues as well as in some cancers. The protein may contain a Rec domain, homologous to retroviral regulatory proteins. Although HERV-K (HML-6) loci show increased transcriptional activity in malignancies such as breast cancer and melanoma, a definitive causal link to disease has not been established. ERVK3-1 is not considered a drug target, receptor, enzyme, or transporter, but is of biological interest due to its transcriptional activity and possible role in disease mechanisms
- Other names
- HERV-K(HML6-1)Endogenous retrovirus group K3, member 1ENSG00000142396105372481
02
Mechanism of action
Not applicable — no known drugs or modulators identified
03
Biological functions
Retroviral sequence element (genomic "fossil" of ancient virus integrations)Has demonstrated transcriptional activity in healthy tissues and in certain cancer typesPossible regulatory functions via encoded proteins, e.g. Rec domainOther
04
Disease associations
Increased transcriptional activity reported in cancer (breast cancer, melanoma)Not directly causal; contribution to disease remains unclearKorean Hemorrhagic Fever (as an association, though this may be a cross-reference rather than a direct role)Other
05
Safety considerations
None recognized as this is not targeted therapeuticallyPotential general challenges relate to the ambiguity of HERV roles in disease or physiology
06
Biomarkers
Not currently established as a clinical biomarkerIncreased transcriptional activity in some cancers (not clinically validated)
Beyond the preview
Go deeper on Endogenous retrovirus group K3 member 1 (ERVK3-1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Endogenous retrovirus group K3 member 1 (ERVK3-1).